Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults

被引：0
作者：
Pace, David [1 ]
机构：
[1] Mater Dei Hosp, Dept Paediat, MSD-2090 Msida, Malta
来源：
FUTURE MICROBIOLOGY | 2010年 / 5卷 / 11期
关键词：
glycoconjugate meningococcal vaccine; MenACWY-CRM; Meningococcal meningitis; CONJUGATE VACCINE; MENACWY-CRM; RANDOMIZED-TRIAL; IMMUNE MEMORY; IMMUNOGENICITY; DISEASE; SAFETY; MENINGITIS; PREVENTION; TOLERABILITY;
D O I：
10.2217/FMB.10.137
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Meningococcal meningitis and septicemia are a persistent public health concern owing to the associated mortality and devastating long-term sequelae. People of all ages may be affected, with the disease burden being higher in at-risk groups. Vaccination is the most rational approach to the prevention of invasive meningococcal disease. A novel quadrivalent meningococcal (Men) serogroup A, C, W-135 and Y polysaccharide-protein conjugate vaccine (MenACWY-CRM), has recently been licensed for use in individuals aged at least 11 years old in the USA, Canada and Europe. One dose of MenACWY-CRM is well tolerated, and induces robust immunity to all constituent vaccine serogroups in 11-65 year old individuals. MenACWY-CRM was found to be noninferior to the quadrivalent meningococcal ACWY-diphtheria toxoid glycoconjugate vaccine, which is also licensed in the USA and Canada. In Europe, MenACWY-CRM is the first quadrivalent meningococcal glycoconjugate vaccine available to provide broader protection against Neissena meningitidis serogroups A, C, W-135 and Y.
引用
收藏
页码：1629 / 1640
页数：12
相关论文
共 46 条
[1]   Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England [J].
Andrews, N ;
Borrow, R ;
Miller, E .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) :780-786
[2]  
Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P273
[3]  
[Anonymous], 2012, CDC Vaccine price list
[4]   Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines [J].
Arguedas, A. ;
Soley, C. ;
Loaiza, C. ;
Rincon, G. ;
Guevara, S. ;
Perez, A. ;
Porras, W. ;
Alvarado, O. ;
Aguilar, L. ;
Abdelnour, A. ;
Grunwald, U. ;
Bedell, L. ;
Anemona, A. ;
Dull, P. M. .
VACCINE, 2010, 28 (18) :3171-3179
[5]   Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases [J].
Bardotti, Angela ;
Averani, Giovanni ;
Berti, Francesco ;
Berti, Stefania ;
Carinci, Valeria ;
D'Ascenzi, Sandro ;
Fabbri, Barbara ;
Glannini, Sara ;
Giannozzi, Aldo ;
Magagnoli, Claudia ;
Proietti, Daniela ;
Norelli, Francesco ;
Rappuoli, Rino ;
Ricci, Stefano ;
Costantino, Paolo .
VACCINE, 2008, 26 (18) :2284-2296
[6]   Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age [J].
Black, S. ;
Klein, N. P. ;
Shah, J. ;
Bedell, L. ;
Karsten, A. ;
Dull, P. M. .
VACCINE, 2010, 28 (03) :657-663
[7]  
BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325
[8]   Meningococcal C conjugate vaccine: The experience in England and Wales [J].
Campbell, Helen ;
Borrow, Ray ;
Salisbury, David ;
Miller, Elizabeth .
VACCINE, 2009, 27 :B20-B29
[9]  
Centers for Disease Control and Prevention, 1999, ACT BACT COR SURV AB
[10]  
Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P1042
12345